Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$553K Sell
27,374
-70,061
-72% -$1.56M ﹤0.01% 2444
2025
Q4
$1.87M Buy
97,435
+70,101
+256% +$1.47M 0.01% 1349
2025
Q3
$658K Sell
27,334
-55,299
-67% -$1.29M ﹤0.01% 1738
2025
Q2
$1.61M Sell
82,633
-181,483
-69% -$2.68M 0.01% 1025
2025
Q1
$3.4M Buy
+264,116
New +$4.25M 0.02% 589
2024
Q2
Sell
-13,000
Closed -$427K 2139
2024
Q1
$427K Buy
+13,000
New +$443K ﹤0.01% 1342
2023
Q3
Sell
-49,969
Closed -$1.91M 2326
2023
Q2
$1.91M Buy
49,969
+36,487
+271% +$1.35M 0.02% 630
2023
Q1
$552K Buy
+13,482
New +$563K 0.01% 1294
2021
Q4
Sell
-12,394
Closed -$513K 3094
2021
Q3
$513K Buy
12,394
+6,248
+102% +$249K ﹤0.01% 1946
2021
Q2
$277K Buy
+6,146
New +$287K ﹤0.01% 2198

Other funds holding ADNT

HRT Financial's ADNT Position: Q1 2026 in Review

HRT Financial reduced its Adient (ADNT) stake by 72% in Q1 2026, selling an estimated $1.56M and leaving 27,374 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

HRT Financial first reported a position in ADNT in Q2 2021 and has held it in 10 quarters since. The position peaked at $3.4M in Q1 2025. 286 funds tracked by Wall St. Rank hold ADNT as of Q1 2026.

  • HRT Financial held 27,374 shares of Adient worth $553K as of Q1 2026.
  • HRT Financial sold 70,061 Adient shares in Q1 2026, an estimated $1.56M.
  • Adient made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2444 holding.
  • HRT Financial first reported a position in Adient in Q2 2021 and has held it in 10 quarters since.
  • HRT Financial's Adient position peaked at $3.4M in Q1 2025.
  • 286 funds tracked by Wall St. Rank held Adient as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.